Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02279459|
Recruitment Status : Completed
First Posted : October 31, 2014
Last Update Posted : May 7, 2019
|Condition or disease|
|Head and Neck Squamous Cell Carcinoma|
Patients with head and/or neck tumors routinely have head and neck imaging completed with a computerized tomography scan, commonly called a CT scan. A CT scan combines a series of x-ray views that are taken from many different angles and uses computer processing to create cross-sectional images inside your body. These cross-sectional images are very thin slices, often less than 1 mm thick and allow the radiologist to examine parts of your tissue very closely.
Dual energy computed tomography (DECT) is a fairly new technology that uses both the normal x-ray and also a second less powerful x-ray to make the images. The Ottawa Hospital has scanners in use that are able to take the images that oncologists typically order for patients and can also be set to obtain DECT images at the same time.
The purpose of this study is to investigate whether DECT images can provide helpful information to better predict how the tumor will respond to treatment and the likely course of head and neck tumors.
|Study Type :||Observational|
|Actual Enrollment :||23 participants|
|Official Title:||Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas: Assessing Tumor Perfusion and Prediction of Treatment Outcomes|
|Actual Study Start Date :||April 14, 2015|
|Actual Primary Completion Date :||October 1, 2018|
|Actual Study Completion Date :||April 15, 2019|
Patients head and neck CT scans performed as standard of care done prior to radiation treatment and approximately 12 weeks following treatment, will be acquired in the dual-energy computed tomography (DECT) mode. Participants will have one additional scan, also in the DECT mode, 2 to 3 weeks after the start of their radiation treatment.
- Correlate iodine quantification with the microvascular density in the biopsy specimen [ Time Frame: up to 18 months ]
- Utility of dual-energy computerized tomography obtained during chemoradiation therapy to predict treatment response. [ Time Frame: up to 18 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02279459
|The Ottawa Hospital|
|Ottawa, Ontario, Canada, K1Y 4E9|
|Principal Investigator:||Santanu Chakraborty, MD||OHRI|